EGFR and lung carcinoma: To determine whether lung tumors harboring mutated-EGFRs are more aggressive than those with WT-EGFR in terms of SBM occurrence, we used a median time interval between the diagnosis of lung cancer and the detection of SBM (MTSBM) as a surrogate of tumor aggressiveness.